Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review

Stamm, Andrew; Adelstein, Sarah A.; Chen, Andrew; Lucioni, Alvaro; Kobashi, Kathleen C.; Lee, Una

doi:10.1016/j.juro.2018.03.132

Cited by 11 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The controversy regarding UTI definitions was also described in a systematic review trying to more accurately examine the UTI rate following botulinum injections; they found that amongst 50 selected publications, only 27 had defined the UTI with a total of 10 different definitions [43]. Two studies used the National Institute on Disability and Rehabilitation Research [44] UTI definition, whereas no studies used a definition which met the European Association of Urology [4] or Infectious Diseases Society of America [41] criteria.…”

Section: Uti: Definitions Diagnoses and Perceptionsmentioning

confidence: 99%

“…Detrusor treatment with Botulinum Toxin A injections efficiently combats neurogenic detrusor overactivity [70] but there is controversy about the UTI rates postinjection [43] and whether there should be antibiotic coverage for the therapeutic sessions [71]. Data from a single SCI rehabilitation centre, comprising 1104 patients with at least 3 years follow-up, found that the odds of a UTI increased 10-fold for those receiving botulinum detrusor injections [6].…”

Section: The Model: Local Urinary Tract Conditionsmentioning

confidence: 99%

See 1 more Smart Citation

Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract Infections

Kennelly

Thiruchelvam

Averbeck

et al. 2019

Advances in Urology

117

View full text Add to dashboard Cite

A risk factor model for urinary tract infections in patients with adult neurogenic lower urinary tract dysfunction performing clean intermittent catheterisation was developed; it consists of four domains, namely, (1) general (systemic) conditions in the patient, (2) individual urinary tract conditions in the patient, (3) routine aspects related to the patient, and (4) factors related to intermittent catheters per se. The conceptual model primarily concerns patients with spinal cord injury, spina bifida, multiple sclerosis, or cauda equina where intermittent catheterisation is a normal part of the bladder management. On basis of several literature searches and author consensus in case of lacking evidence, the model intends to provide an overview of the risk factors involved in urinary tract infections, with specific emphasis to describe those that in daily practice can be handled and modified by the clinician and so come to the benefit of the individual catheter user in terms of fewer urinary tract infections.

show abstract

Section: Uti: Definitions Diagnoses and Perceptionsmentioning

confidence: 99%

Section: The Model: Local Urinary Tract Conditionsmentioning

confidence: 99%

Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract Infections

Kennelly

Thiruchelvam

Averbeck

et al. 2019

Advances in Urology

117

View full text Add to dashboard Cite

show abstract

“…We also followed the European Association of Urology guidelines for UTI diagnostic criteria in the subanalysis since UTI definitions have been inconsistent among studies. 16 Another group assessing men and women undergoing their first intravesical BTX-A injection for refractory idiopathic detrusor overactivity found that women were more likely to have a UTI after injection . 17 However, as women are at higher risk for UTI at baseline, it is unclear whether recent UTIs (prior to injection) played an additional role in their study.…”

Section: Discussionmentioning

confidence: 99%

Does a Recent Urinary Tract Infection Increase the Risk of Postprocedure Urinary Tract Infection After Onabotulinum Toxin A?

Bickhaus

Bradley

Amundsen

et al. 2021

Female Pelvic Med Reconstr Surg

View full text Add to dashboard Cite

Objectives: To evaluate the risk of post-procedure urinary tract infection after injection of onabotulinumtoxin A in women who had a urinary tract infection within 30 days prior to procedure. Methods:This was a retrospective cohort study of women who underwent their first injection of onabotulinumtoxin A from 2010 to 2016. Two cohorts were identified: 1) recent urinary tract infection (within 30 days prior to injection); and 2) no recent urinary tract infection. Our primary outcome was urinary tract infection within 90 days after onabotulinumtoxin A. Continuous variables were analyzed using the Wilcoxon rank sum test and categorical variables were analyzed using Fisher's exact or X 2 tests.Results: One hundred sixty-six women underwent their first onabotulinumtoxin A injection. Twenty-five (15%) had a recent urinary tract infection and 141 (85%) did not. Women with a recent urinary tract infection were more likely to have a subsequent infection (52% vs. 26%, p < 0.01). However, in a logistic regression model, controlling for history of recurrent urinary tract infection, age, history of diabetes mellitus, periprocedural antibiotics, and urinary retention

show abstract

“…8 The incidence of bacteriuria after cystoscopic intravesical injection of BoNT-A is high 9 and there is debate as to what constitutes symptomatic urinary tract infection (UTI) following intravesical injection of BoNT-A. 10 The rate of postoperative UTI is accepted to be about 15%. 11 Perioperative antibiotic prophylaxis is therefore recommended to reduce the risk of postoperative UTI.…”

Section: Introductionmentioning

confidence: 99%

Prophylactic intravenous gentamicin with sedation-free cystoscopic injection of BoNT-A: No demonstrable adverse extravesical neuromuscular effects in a pilot safety study of 220 idiopathic overactive bladder patients

Napier-Hemy

Feyisetan

Stewart

et al. 2021

Journal of Clinical Urology

View full text Add to dashboard Cite

Objectives: To determine whether administration of single dose prophylactic intravenous gentamicin prior to intravesical injection of botulinum toxin type A (BoNT-A) is associated with adverse extravesical neuromuscular effects in idiopathic overactive bladder syndrome. Patients and methods: A retrospective analysis of 220 consecutive idiopathic overactive bladder patients following sedation-free flexible cystoscopic injection of intravesical BoNT-A. All patients received a single dose of intravenous gentamicin (160 mg) followed by 100-200 IU of BoNT-A. They were followed up at intervals to determine whether they had experienced any adverse extravesical neuromuscular side effects. Results: None of our patients developed adverse extravesical neuromuscular side effects from intravesical botulinum injections with concomitant administration of intravenous gentamicin. Conclusion: Single dose intravenous gentamicin is safe to use as a prophylaxis for intravesical BoNT-A injections of 200 IU or below in idiopathic overactive bladder patients. Level of evidence: Not applicable.

show abstract

Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review

Cited by 11 publications

References 15 publications

Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract Infections

Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract Infections

Does a Recent Urinary Tract Infection Increase the Risk of Postprocedure Urinary Tract Infection After Onabotulinum Toxin A?

Prophylactic intravenous gentamicin with sedation-free cystoscopic injection of BoNT-A: No demonstrable adverse extravesical neuromuscular effects in a pilot safety study of 220 idiopathic overactive bladder patients

Contact Info

Product

Resources

About